Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R) Milica PešićTijana AndjelkovićSabera Ruždijić PRECLINICAL STUDIES 21 May 2008 Pages: 99 - 110
Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growth Masaharu HazawaKoji WadaIkuo Kashiwakura PRECLINICAL STUDIES 13 June 2008 Pages: 111 - 119
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer Manon BuijsJosephina A. VossenMustafa Vali PRECLINICAL STUDIES 14 June 2008 Pages: 120 - 123
In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo Angela AlamaMaurizio VialeFabio Sparatore PRECLINICAL STUDIES 19 June 2008 Pages: 124 - 130
Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: a structure–activity relationship study Ananda Kumar C. S.S. B. Benaka PrasadK. S. Rangappa PHASE I STUDIES 08 July 2008 Pages: 131 - 139
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820 Ron J. KeizerMiren K. ZamaconaAlwin D. R. Huitema Phase I Studies 20 August 2008 Pages: 140 - 152
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies H. SayarZ. ShenC. Verschraegen PHASE I STUDIES 05 September 2008 Pages: 153 - 158
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer Elaina M. GartnerKent A. GriffithMark M. Zalupski Phase II Studies 20 August 2008 Pages: 159 - 165
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy) G. SchillingM. BruweleitM. de Wit Phase II Studies 12 August 2008 Pages: 166 - 172
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients Noor Al-DasooqiJoanne M. BowenDorothy M. Keefe SHORT REPORT 09 July 2008 Pages: 173 - 178
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer Giuseppe GulloDaniela BettioArmando Santoro SHORT REPORT Open access 29 July 2008 Pages: 179 - 183
Bowel perforation in non-small cell lung cancer after bevacizumab therapy Elisabeth SchellhaasChristoph LoddenkemperUwe Pohlen SHORT REPORT 30 July 2008 Pages: 184 - 187